Support Line: 0300 373 8500
This study is looking at how a new type of BTK inhibitor, Pirtobrutinib, works in patients with certain types of lymphoma, including WM.
It is split into different phases, giving researchers insight into what the best dosage is, and how it might work with other treatments. Pirtobrutinib is different to other BTK inhibitors as it reacts differently with the cells they target.
This study is on-going but currently closed to recruitment.
• Confirmed diagnosis of WM;
• You were intolerant to 2 or more standard care regimens or received a BTK inhibitor as first line treatment
